Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Haoxi Health Technology Ltd files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2024
FY2024
FY2025
Revenue
16.2
28.2
48.5
32.8
Cost of revenue
15.5
26.2
45.8
31.9
Gross profit
0.65
2.06
2.75
0.93
Research and development
0.1
0.06
0.08
0.08
General and administrative
0.24
0.78
0.91
2.8
Operating expenses
0.38
0.87
1.03
2.93
Operating income
0.27
1.2
1.72
-2
Interest expense
0.02
0.04
0.05
Interest income
0.08
0.36
Other non-operating income
-0.01
-0.01
0.02
6.15
Pre-tax income
0.26
1.19
1.74
4.15
Income tax
0.02
0.22
0.44
0.27
Net income
0.24
0.97
1.29
3.88
EBITDA
0.27
1.2
1.73
-1.71
EPS, basic
0.22
0.87
1.06
1.66
EPS, diluted
0.22
0.87
1.06
1.32
Shares, basic (weighted)
1.15
1.1
1.22
2.33
Shares, diluted (weighted)
1.15
1.1
1.22
2.4
Balance sheet
FY2022
FY2024
FY2024
FY2025
Cash and equivalents
0.29
1.2
6.66
8.62
Receivables
0.01
0.23
0.46
Other current assets
0.06
3.35
4.85
Total current assets
3.67
15.4
19.6
Property, plant and equipment
0.14
0.13
0.11
Lease right-of-use assets
0.09
0.08
Intangible assets
1.8
Total assets
4.46
15.5
21.6
Accounts payable
0.03
0.65
0.15
Accrued liabilities
0.04
0.04
0.03
Deferred revenue
1.19
0.54
Short-term debt
0.03
0.83
0.3
Total current liabilities
2.58
3.87
3.89
Long-term debt
0.25
0.3
0.31
Other non-current liabilities
0.07
0.07
Total liabilities
2.9
4.23
4.22
Total debt
0.28
0.3
0.61
Paid-in capital
2.18
10.6
12.8
Retained earnings
-0.57
0.72
4.6
Other comprehensive income
-0.04
-0.04
-0.05
Shareholders' equity
-1.47
1.57
11.3
17.4
Total equity
-1.47
1.57
11.3
17.4
Total liabilities and equity
4.46
15.5
21.6
Cash flow statement
FY2022
FY2024
FY2024
FY2025
Net income
0.24
0.97
1.29
3.88
Depreciation and amortization
0
0.01
0.01
0.29
Stock-based compensation
0.06
Change in receivables
0.67
-0
-0.22
-0.25
Change in payables
-1.6
-1.2
0.62
Cash from operations
-0.68
-0.87
-0.75
-3.36
Capital expenditures
-0.01
-0.05
-0.06
Cash from investing
-0.01
-0.05
-3.13
-3.58
Debt issued
0.26
Debt repaid
-0.07
-0.04
Stock issued
0.16
1.99
8.98
Cash from financing
0.93
1.8
9.32
8.9
Exchange rate effect
-0.01
0.02
0.01
-0
Net change in cash
0.24
0.91
5.45
1.96
Free cash flow
-0.68
-0.92
-0.8
Interest paid
0
0.02
0.04
0.04
Income taxes paid
0.01
0.03
0.01
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $2.90 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
2.8%
Gross profit / revenue.
Operating margin
-6.1%
Operating income / revenue.
EBITDA margin
-5.2%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
12.6%
Pre-tax income / revenue.
Net margin
11.8%
Net income / revenue.
Operating cash flow margin
-10.2%
Cash from operations / revenue.
Effective tax rate
6.5%
Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)
27.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
20.9%
Net income / average total assets.
Return on invested capital (ROIC)
-26.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
0.2%
Research and development expense / revenue.
Stock-based pay / revenue
0.2%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
0.9%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-32.4%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
26.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
-66.3%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
12.7%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income growth, 1y
-216.5%
Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y
-198.7%
EBITDA vs the same period a year earlier. Only from a positive base.
Net income growth, 1y
200.1%
Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y
151.2%
Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS growth, 1y
24.5%
EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y
82.4%
Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
54.2%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
39.3%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
95.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
27.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.05x
Current assets / current liabilities.
Quick ratio
2.34x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.22x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.03x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
2.8%
Total debt / total assets.
Liabilities / assets
19.5%
Total liabilities / total assets.
Net debt
-$8.0M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
$1.66
Net income per basic share, as reported (split-adjusted).
Revenue per share
$13.69
Revenue / diluted weighted shares.
Operating cash flow per share
-$1.40
Cash from operations / diluted weighted shares.
Book value per share
$7.25
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
0.27x
Market cap / net income. Only when net income is positive.
P/S
0.03x
Market cap / revenue.
P/B
0.06x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.07x
Market cap / tangible book value, when positive.
Earnings yield
365.1%
Net income / market cap (the inverse of P/E).
PEG
0.00x
P/E / EPS growth per year over 3 years (in percent). Only when both are positive.
What was Haoxi Health Technology Ltd's revenue in fiscal 2025?
Haoxi Health Technology Ltd reported revenue of $32.8M for fiscal 2025, 32.4% lower than the year before.
Was Haoxi Health Technology Ltd profitable in fiscal 2025?
Yes. Net income was $3.9M, a net margin of 11.8%.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.